Skip to main content

Autism clinical trials at UCSF
4 in progress, 3 open to new patients

  • A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)

    open to eligible people ages 3–8

    The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism in children with all levels of fecal chymotrypsin.

    San Francisco, California and other locations

  • An Open Label Study of CM-AT for the Treatment of Children With Autism

    open to eligible people ages 3–17

    This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.

    San Francisco, California and other locations

  • Dyad Oxytocin Study (DOS)

    open to eligible people ages 18–75

    The purpose of the investigators proposed study is twofold: 1) To investigate the role of the affiliative neuropeptide oxytocin in unhealthy interactions in families of patients with schizophrenia and families of patients with autism spectrum disorder, and 2) to investigate whether manipulation of this oxytocinergic system positively influences these family interactions.

    San Francisco, California

  • Pediatric Open-Label Extension Study

    Sorry, in progress, not accepting new patients

    This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326

    San Francisco, California and other locations